Published May 8, 2012 on drugwatch When Dr. Steve Nissen, one of the top cardiologists in the country, heralded the death knell for Avandia by finding the diabetes drug increased the risk of heart attack and found that its competitor Actos lowered the risk, the good doctor was hailed as the unsung hero to diabetes Full Article…
Search LawsuitInformation.org
Viewing 1 to 10 of 12 items
Avandia Lawsuit Settlements
Posted April 22, 2012 Rosiglitazone, branded under Avandia and marketed as a drug to help diabetics process insulin by manufacturer GlaxoSmithKline, has been the focus of several lawsuits in the United States and Europe. Due to the reported side effects, Avandia declined in popularity and is now subject to restrictions placed by the Food and Full Article…
Comments Off
Antidiabetic Drug Avandia To Be Pulled From Retail
Posted May 24, 2011 on TheAdvertiser USA TODAY The diabetes drug Avandia will be pulled from retail pharmacy shelves in November because it poses such a big heart attack risk, the federal government announced Tuesday. When the new program goes into effect on Nov. 18, only certified doctors will be allowed to prescribe the drug, Full Article…
Comments Off
Can Actos Prevent Diabetes?
Posted March 30, 2011 on ACHS.com After allegations were made linking the diabetes drug rosiglitazone (Avandia) to an increased risk of heart attack, it was taken off the market in Europe, and its use was severely restricted here by the FDA. Now a new study in the New England Journal of Medicine gives hope that Full Article…
Comments Off
Glaxo’s Legal Problems Lead to New $3.4 Billion Charge
Posted January 17, 2011 on NY Times The British drug maker GlaxoSmithKline announced Monday that it was setting aside $3.4 billion — wiping out fourth-quarter profit — to pay for United States government investigations and product liability cases over its marketing of the diabetes drug Avandia. The one-time charge is expected to exceed GlaxoSmithKline’s quarterly Full Article…
Comments Off
Diabetes Drug Maker Hid Test Data, Files Indicate
Posted July 13, 2010 by NY Times In the fall of 1999, the drug giant SmithKline Beecham secretly began a study to find out if its diabetes medicine, Avandia, was safer for the heart than a competing pill, Actos, made by Takeda. Avandia’s success was crucial to SmithKline, whose labs were otherwise all but barren Full Article…
Comments Off
Glaxo Memo on Avandia Is Questioned
Posted August 19, 2010 by NY Times Federal drug regulators ordered GlaxoSmithKline to send a letter to key doctors describing a July expert advisory panel that discussed the risks of Avandia, the company’s controversial diabetes medicine. But the company’s letter is misleading and could endanger patients, a federal official and some members of the panel Full Article…
Comments Off
F.D.A. to Restrict Avandia, Citing Heart Risk
Posted September 23, 2010 by NY Times WASHINGTON — In a highly unusual coordinated announcement, drug regulators in Europe and the United States said Thursday that Avandia, the controversial diabetes medicine, would no longer be widely available. The drug’s sales will be suspended entirely in Europe, while patients in the United States will be allowed Full Article…
Comments Off
Avandia Raises Heart Failure Risk More Than Actos
Posted August 18, 2010 on Health.com TUESDAY, Aug. 18 (HealthDay News) — The type 2 diabetes drug Avandia (rosiglitazone) increases the risk of heart failure and death more than another drug in the same class, Actos (pioglitazone), new Canadian research contends. Avandia has been the subject of controversy since 2007, when it was linked to Full Article…
Comments Off
Avandia Study with Industry Ties Receives JAMA Rebuke
Posted March 27, 2010 by Carey & Danis When it comes to a “disturbing example of inappropriate conduct surrounding an industry-sponsored clinical trial,” a GlaxoSmithKline study of its diabetes drug Avandia is being held out as Exhibit A in an editorial that appeared in the March 23 issue of the Journal of the American Medical Full Article…
Comments Off
